Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
Arimidex, Faslodex
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Crixotinib 200 mg and Sunitinib Cohort 1, Crixotinib 250 mg and Sunitinib Cohort 2, Crizotinib & Sunitinib 37.5 mg Cohort 3
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
BREAST CANCER
Interventions
Herceptin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 2 Interventional Results available

High Dose Vitamin D vs Standard Dose Vitamin D Study

NCT01988090
Conditions
Breast Cancer
Interventions
800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

NCT02547987
Conditions
Breast Cancer
Interventions
Docetaxel, Carboplatin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas